Back to Search
Start Over
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma.
- Source :
-
Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2021 Nov; Vol. 43 Suppl 2, pp. S22-S29. - Publication Year :
- 2021
-
Abstract
- The treatment and evolution of B-cell non-Hodgkin lymphoma (B-NHL) has undergone important changes in the last years with the emergence of targeted therapies, such as monoclonal antibodies, small molecules, antibody-drug conjugates, and bispecific antibodies. Nevertheless, a significant portion of patients remains refractory or relapsed (R/R) to the new therapeutic modalities, representing thus an unmet medical need. The use of CAR-T cells for the treatment of B-NHL patients has shown to be a promising therapy with impressive results in patients with R/R disease. The expectations are as high as the imminent approval of CAR-T cell therapy in Brazil, which it is expected to impact the prognosis of R/R B-NHL. The aim of this manuscript is to offer a consensus of specialists in the field of onco-hematology and cellular therapy, working in Brazil and United States, in order to discuss and offer recommendations in the present setting of the use of CAR-T cells for patients with B-NHL.<br />Competing Interests: Conflicts of interest The authors declare no conflicts of interest.<br /> (Copyright © 2021. Published by Elsevier España, S.L.U.)
Details
- Language :
- English
- ISSN :
- 2531-1387
- Volume :
- 43 Suppl 2
- Database :
- MEDLINE
- Journal :
- Hematology, transfusion and cell therapy
- Publication Type :
- Academic Journal
- Accession number :
- 34794792
- Full Text :
- https://doi.org/10.1016/j.htct.2021.09.003